Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

L Mockeliunas, A Faraj, RC Van Wijk… - Frontiers in …, 2023 - frontiersin.org
Background: A critical step in tuberculosis (TB) drug development is the Phase 2a early
bactericidal activity (EBA) study which informs if a new drug or treatment has short-term …

[HTML][HTML] Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium

RC Van Wijk, A Lucía, PK Sudhakar, L Sonnenkalb… - Iscience, 2023 - cell.com
Tuberculosis (TB) is the historical leading cause of death by a single infectious agent. The
European Regimen Accelerator for Tuberculosis (ERA4TB) is a public-private partnership of …

Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes

ZH Temrikar, S Kodidela, S Kumar, J Liu, GT Robertson… - Tuberculosis, 2023 - Elsevier
Spectinamides are a novel series of spectinomycin analogs being developed for the
treatment of tuberculosis. The preclinical lead spectinamide 1599 is an antituberculosis drug …

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development

R Ayoun Alsoud, RJ Svensson, EM Svensson… - Frontiers in …, 2023 - frontiersin.org
Biomarkers are quantifiable characteristics of biological processes. In Mycobacterium
tuberculosis, common biomarkers used in clinical drug development are colony forming unit …

[图书][B] PKPD-Model Based Preclinical Characterization of the Activity of Spectinamide 1599 Against Mycobacterial Subpopulations and the Identification of Potential …

ZH Temrikar - 2023 - search.proquest.com
Tuberculosis is one of the top 10 causes of death worldwide and the leading cause of death
from a single infectious agent prior to COVID19. Mycobacterium tuberculosis (Mtb) is the …